{
    "Trade/Device Name(s)": [
        "CEDIA Heroin Metabolite (6-AM) Assay"
    ],
    "Submitter Information": "Microgenics Corporation",
    "510(k) Number": "K192943",
    "Predicate Device Reference 510(k) Number(s)": [
        "K173183"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "DJG"
    ],
    "Summary Letter Date": "October 17, 2019",
    "Summary Letter Received Date": "October 18, 2019",
    "Submission Date": "",
    "Regulation Number(s)": [
        "21 CFR 862.3650"
    ],
    "Regulation Name(s)": [
        "Opiate test system"
    ],
    "Analyte Class(es)": [
        "toxicology"
    ],
    "Analyte(s)": [
        "Heroin",
        "6-Acetylmorphine"
    ],
    "Specimen Type(s)": [
        "Urine"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "Clinical chemistry analyzers",
        "Horiba Pentra C400",
        "Beckman AU680"
    ],
    "Method(s)/Technology(ies)": [
        "Homogeneous enzyme immunoassay",
        "CEDIA"
    ],
    "Methodologies": [
        "Immunoassay"
    ],
    "Submission Type(s)": [
        "Assay",
        "Reagent"
    ],
    "Document Summary": "FDA 510(k) summary for CEDIA Heroin Metabolite (6-AM) Assay for qualitative and semi-quantitative detection of heroin metabolite in urine using homogeneous enzyme immunoassay technology.",
    "Indications for Use Summary": "Qualitative and/or semi-quantitative in vitro determination of heroin metabolite (6-AM) in human urine at a 10 ng/mL cut-off for rapid analytical screening; laboratories use with clinical chemistry analyzers, results require confirmation by specific alternative chemical methods.",
    "fda_folder": "Toxicology"
}